Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2015 1
2016 4
2017 3
2018 3
2019 2
2020 1
2021 2
2022 4
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Yang JC, et al. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12. Lancet Oncol. 2015. PMID: 25589191 Free article. Clinical Trial.
METHODS: Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-c …
METHODS: Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 ( …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Park K, et al. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
METHODS: This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centres in 13 countries. Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were …
METHODS: This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 c …
Circadian protein expression patterns in healthy young adults.
Specht A, Kolosov G, Cederberg KLJ, Bueno F, Arrona-Palacios A, Pardilla-Delgado E, Ruiz-Herrera N, Zitting KM, Kramer A, Zeitzer JM, Czeisler CA, Duffy JF, Mignot E. Specht A, et al. Sleep Health. 2024 Feb;10(1S):S41-S51. doi: 10.1016/j.sleh.2023.10.005. Epub 2023 Dec 11. Sleep Health. 2024. PMID: 38087675
Age-related changes in circadian regulation of the human plasma lipidome.
Rahman SA, Gathungu RM, Marur VR, St Hilaire MA, Scheuermaier K, Belenky M, Struble JS, Czeisler CA, Lockley SW, Klerman EB, Duffy JF, Kristal BS. Rahman SA, et al. Commun Biol. 2023 Jul 20;6(1):756. doi: 10.1038/s42003-023-05102-8. Commun Biol. 2023. PMID: 37474677 Free PMC article.
Robust perceptual-load-dependent audiovisual integration in adult ADHD.
Schulze M, Aslan B, Jung P, Lux S, Philipsen A. Schulze M, et al. Eur Arch Psychiatry Clin Neurosci. 2022 Dec;272(8):1443-1451. doi: 10.1007/s00406-022-01401-z. Epub 2022 Apr 5. Eur Arch Psychiatry Clin Neurosci. 2022. PMID: 35380238 Free PMC article.
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K. Wu YL, et al. Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17. Clin Lung Cancer. 2018. PMID: 29653820 Free article. Clinical Trial.
PATIENTS AND METHODS: Treatment-naive patients with advanced EGFRm(+) NSCLC were randomized to afatinib (40 mg/d) versus cisplatin/pemetrexed (LUX-Lung 3 [LL3]) or cisplatin/gemcitabine (LUX-Lung 6 [LL6]), or versus gefitinib (250 mg/d; LUX-Lung 7 [LL7]). ...
PATIENTS AND METHODS: Treatment-naive patients with advanced EGFRm(+) NSCLC were randomized to afatinib (40 mg/d) versus cisplatin/pemetrexe …
Eating during the biological night is associated with nausea.
Zitting KM, Isherwood CM, Yuan RK, Wang W, Vujovic N, Münch M, Cain SW, Williams JS, Buxton OM, Czeisler CA, Duffy JF. Zitting KM, et al. Sleep Health. 2024 Feb;10(1S):S144-S148. doi: 10.1016/j.sleh.2023.08.004. Epub 2023 Sep 18. Sleep Health. 2024. PMID: 37730474
34 results